← All trials
NCT01603303
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2012
- Primary completion
- Aug 11, 2017
- Completion date
- Aug 11, 2017
- First posted
- May 22, 2012
- Last posted
- Aug 18, 2017
- Enrollment
- 187
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- Fidia Advanced BiopolymersCollaborator
- University of Texas at HoustonOverall official - principal investigator
- University of Texas at HoustonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.